| Landscape of somatic mutations in 560 breast cancer whole-genome sequences S Nik-Zainal, H Davies, J Staaf, M Ramakrishna, D Glodzik, X Zou, ... Nature 534 (7605), 47-54, 2016 | 2283 | 2016 |
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1704 | 2017 |
| Efficacy and safety of vismodegib in advanced basal-cell carcinoma A Sekulic, MR Migden, AE Oro, L Dirix, KD Lewis, JD Hainsworth, ... New England Journal of Medicine 366 (23), 2171-2179, 2012 | 1666 | 2012 |
| Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2–negative metastatic … DW Miles, A Chan, LY Dirix, J Cortés, X Pivot, P Tomczak, T Delozier, ... Journal of clinical oncology 28 (20), 3239-3247, 2010 | 1092 | 2010 |
| Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data FC Bidard, DJ Peeters, T Fehm, F Nolé, R Gisbert-Criado, D Mavroudis, ... The lancet oncology 15 (4), 406-414, 2014 | 955 | 2014 |
| Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation PB Vermeulen, G Gasparini, SB Fox, M Toi, L Martin, P McCulloch, ... European Journal of Cancer 32 (14), 2474-2484, 1996 | 944 | 1996 |
| Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study LY Dirix, I Takacs, G Jerusalem, P Nikolinakos, HT Arkenau, ... Breast cancer research and treatment 167, 671-686, 2018 | 732 | 2018 |
| Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial M Kaufmann, E Bajetta, LY Dirix, LE Fein, SE Jones, N Zilembo, ... Journal of Clinical Oncology 18 (7), 1399-1411, 2000 | 692 | 2000 |
| Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours PB Vermeulen, G Gasparini, SB Fox, C Colpaert, LP Marson, M Gion, ... European journal of cancer 38 (12), 1564-1579, 2002 | 642 | 2002 |
| Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer HJ Burstein, Y Sun, LY Dirix, Z Jiang, R Paridaens, AR Tan, A Awada, ... Journal of Clinical Oncology 28 (8), 1301-1307, 2010 | 637 | 2010 |
| Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial MR Patel, J Ellerton, JR Infante, M Agrawal, M Gordon, R Aljumaily, ... The Lancet Oncology 19 (1), 51-64, 2018 | 611 | 2018 |
| Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer R Salgado, S Junius, I Benoy, P Van Dam, P Vermeulen, E Van Marck, ... International journal of cancer 103 (5), 642-646, 2003 | 594 | 2003 |
| Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel M Aapro, PA Abrahamsson, JJ Body, RE Coleman, R Colomer, L Costa, ... Annals of oncology 19 (3), 420-432, 2008 | 586 | 2008 |
| International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment S Dawood, SD Merajver, P Viens, PB Vermeulen, SM Swain, TA Buchholz, ... Annals of oncology 22 (3), 515-523, 2011 | 553 | 2011 |
| Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind … SB Kim, R Dent, SA Im, M Espié, S Blau, AR Tan, SJ Isakoff, M Oliveira, ... The Lancet Oncology 18 (10), 1360-1372, 2017 | 516 | 2017 |
| Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse M Brada, K Hoang-Xuan, R Rampling, PY Dietrich, LY Dirix, D Macdonald, ... Annals of Oncology 12 (2), 259-266, 2001 | 482 | 2001 |
| Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial MR Migden, A Guminski, R Gutzmer, L Dirix, KD Lewis, P Combemale, ... The Lancet Oncology 16 (6), 716-728, 2015 | 462 | 2015 |
| Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer SA Hurvitz, L Dirix, J Kocsis, GV Bianchi, J Lu, J Vinholes, E Guardino, ... Journal of Clinical Oncology 31 (9), 1157-1163, 2013 | 449 | 2013 |
| Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases S Frentzas, E Simoneau, VL Bridgeman, PB Vermeulen, S Foo, ... Nature medicine 22 (11), 1294-1302, 2016 | 429 | 2016 |
| Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study E Van Cutsem, M Findlay, B Osterwalder, W Kocha, D Dalley, R Pazdur, ... Journal of Clinical Oncology 18 (6), 1337-1345, 2000 | 425 | 2000 |
